Funding for the first closing of Apta Biosciences’s Ltd opening funding round
Ranworth Capital is pleased to announce it has underwritten the funding for the first closing of Apta Biosciences’s Ltd opening funding round. This is via a mixture of equity and convertible loan notes. Ranworth has also taken an option to place additional investment at the second closing.
Apta Biosciences Ltd is an exciting new company spun out of Fujitsu, with the purpose of developing and commercialising its Modified DNA Aptamers as a synthetic alternative to antibodies for both Diagnostics and Therapeutics. Apta Biosciences holds 25 patents for its novel method of aptamer development that shows the potential for higher affinities than commercially available antibodies.
Fred Edenius, Founder/Director of Apta Biosciences commented:
”This is an important investment for Apta, and we are delighted that Ranworth have decided to underwrite this opening investment round. We see Ranworth Capital as an ideal investment partner because of their core values and flexibility. They bring to the table much more than finance, their in-house experience and network of contacts are much valued.”